NRx Pharmaceuticals, Inc. (NRXP)
NASDAQ: NRXP · Real-Time Price · USD
3.530
-0.480 (-11.97%)
At close: Jan 21, 2025, 4:00 PM
3.540
+0.010 (0.28%)
After-hours: Jan 21, 2025, 7:25 PM EST
NRx Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for NRx Pharmaceuticals stock have an average target of 31.67, with a low estimate of 19 and a high estimate of 45. The average target predicts an increase of 797.17% from the current stock price of 3.53.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for NRXP stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $31 | Strong Buy | Maintains | $31 | +778.19% | Jan 6, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $31 | Strong Buy | Maintains | $31 | +778.19% | Jan 2, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $31 | Strong Buy | Maintains | $31 | +778.19% | Dec 31, 2024 |
| Ascendiant Capital | Ascendiant Capital | Strong Buy Maintains $44 → $45 | Strong Buy | Maintains | $44 → $45 | +1,174.79% | Dec 2, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +438.24% | Nov 25, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
69.85M
EPS This Year
-1.94
from -3.98
EPS Next Year
-0.17
from -1.94
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | 112.6M | 189.3M | |||
| Avg | n/a | 69.8M | 183.9M | |||
| Low | n/a | 37.4M | 176.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | 171.0% | |||
| Avg | - | - | 163.3% | |||
| Low | - | - | 153.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -1.84 | 0.02 | 1.90 |
| Avg | -1.94 | -0.17 | 1.85 |
| Low | -1.95 | -0.42 | 1.77 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.